Brainstorm Cell Therapeutics reported $-6771000 in EBITDA for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Biogen BIIB:US USD 992.8M 82.9M
Brainstorm Cell Therapeutics BCLI:US USD -6771000 749K
Cytokinetics CYTK:US USD -107033000 97.57M
Gilead Sciences GILD:US USD 3.28B 731M
Halozyme Therapeutics HALO:US USD 112.9M 66.29M
Idera Pharmaceuticals IDRA:US USD -3686000 1.67M